Aligos Therapeutics Inc [NASDAQ: ALGS] jumped around 0.84 points on previous day while shares priced at $8.37 at the close of the session, up 11.16%.
Compared to the average trading volume of 157.79K shares, ALGS reached a trading volume of 110386 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Aligos Therapeutics Inc [ALGS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALGS shares is $85.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALGS stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Aligos Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 19, 2024. While these analysts kept the previous recommendation, Piper Sandler raised their target price from $2 to $3. The new note on the price target was released on January 06, 2023, representing the official price target for Aligos Therapeutics Inc stock. Previously, the target price had yet another raise from $2.50 to $3, while Jefferies kept a Buy rating on ALGS stock. On March 23, 2022, analysts decreased their price target for ALGS shares from 15 to 4.
The Average True Range (ATR) for Aligos Therapeutics Inc is set at 0.75, with the Price to Sales ratio for ALGS stock in the period of the last 12 months amounting to 15.65. The Price to Book ratio for the last quarter was 0.44, with the Price to Cash per share for the same quarter was set at 22.57.
How has ALGS stock performed recently?
Aligos Therapeutics Inc [ALGS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.08. With this latest performance, ALGS shares gained by 42.11% in over the last four-week period, additionally sinking by -75.43% over the last 6 months – not to mention a drop of -33.04% in the past year of trading.
Aligos Therapeutics Inc [ALGS]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Aligos Therapeutics Inc [ALGS] shares currently have an operating margin of -2640.70% and a Gross Margin at 34.50%. Aligos Therapeutics Inc’s Net Margin is presently recorded at -1628.75%.
Return on Equity for this stock declined to -38.23%, with Return on Assets sitting at -38.23%.
Earnings analysis for Aligos Therapeutics Inc [ALGS]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALGS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Aligos Therapeutics Inc go to 23.56%.
Insider trade positions for Aligos Therapeutics Inc [ALGS]
The top three institutional holders of ALGS stocks are: ARMISTICE CAPITAL, LLC with ownership of 7.26 million shares, which is approximately 4.6383%. ECOR1 CAPITAL, LLC, holding 6.39 million shares of the stock with an approximate value of $$2.24 million in ALGS stocks shares; and ECOR1 CAPITAL, LLC, currently with $$2.14 million in ALGS stock with ownership which is approximately 3.9009%.
